Lisata Therapeutics (LSTA) LD Micro Main Event XVI summary

Strategic positioning and technology

• Proprietary technology with IP protection into the 2040s and a seasoned management team with extensive international development experience.

• Multiple business development and clinical milestones projected over the next 12–18 months.

• Cash reserves projected to fund operations and all current development programs through 2026.

• Oncology focus driven by the high global burden and cost of solid tumors, with 90% of new US cancer cases being solid tumors.

Scientific rationale and mechanism

• Solid tumors present physical and immunological barriers that limit treatment efficacy and survival.

• Certepetide, a cyclic internalizing RGD peptide, targets tumor stroma and microenvironment, converting barriers into conduits and recruiting cytotoxic T cells.

• The agent is agnostic to companion therapy modality, enabling broad combination potential.

• Mechanism involves binding to integrins, proteolytic cleavage, and activation of neuropilin-1 for active transport of anti-cancer agents.

Preclinical and clinical evidence

• Over 350 peer-reviewed publications support improved efficacy of anti-cancer agents when combined with certepetide.

• Preclinical models show enhanced survival, tumor uptake, and reduced metastases across multiple solid tumor types.

• Clinical trials in Australia and China demonstrate consistent improvements in overall survival and efficacy measures in metastatic patients.

• Compassionate use case showed complete remission in a patient with metastatic gastroesophageal adenocarcinoma.